Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Net Income (2021 - 2025)

Historic Net Income for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' Net Income fell 1659.63% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 657.27%. This contributed to the annual value of -$41.9 million for FY2024, which is 59.45% up from last year.
  • SAB Biotherapeutics' Net Income amounted to -$12.1 million in Q3 2025, which was down 1659.63% from -$9.8 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Net Income registered a high of $1.4 million during Q1 2021, and its lowest value of -$22.9 million during Q4 2023.
  • For the 5-year period, SAB Biotherapeutics' Net Income averaged around -$7.5 million, with its median value being -$7.3 million (2024).
  • As far as peak fluctuations go, SAB Biotherapeutics' Net Income plummeted by 84592.72% in 2023, and later skyrocketed by 5649.72% in 2024.
  • SAB Biotherapeutics' Net Income (Quarter) stood at -$11.6 million in 2021, then soared by 32.05% to -$7.8 million in 2022, then crashed by 191.21% to -$22.9 million in 2023, then skyrocketed by 56.5% to -$9.9 million in 2024, then decreased by 21.36% to -$12.1 million in 2025.
  • Its Net Income was -$12.1 million in Q3 2025, compared to -$9.8 million in Q2 2025 and -$10.8 million in Q1 2025.